Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?

Recent growing understanding on mechanisms of aging as gradual changes in body systems through several cellular and molecular levels has raised research interests in the biology of aging. There are seven established overlapping processes of aging: oxidative stress, macromolecular damage, epigenetic changes, abnormal metabolism, impaired proteostasis, decline in stem cell functions and inflammation. These overlapping changes over the lifetime affect the onset of age-related diseases and possibly the aging process itself. However, lifestyle and pharmacologic interventions can modify the deterioration of aging pathways. AKG is a generally regarded as safe (GRAS) micronutrient and has shown great potential in extending healthspan. Here, we aim to study the role of AKG in the modulation of aging.

The aim is to evaluate the anti-aging function of AKG and determine whether AKG can modulate biological pathways of aging in middle-aged adults in Singapore. Our hypothesis is that AKG will affect DNA methylation which will be associated with the change in blood biomarkers of aging and change in physiological function. It allows us to study the longitudinal effects of AKG on clinical and biological outcomes.

This is a 6-month double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants to study the effect of AKG on biomarkers of aging, with another 3 months of post-intervention follow-up. The total duration of participation in this study is 9 months.

The rationale for this study design is to study the long-term effect of 1 g AKG in middle-aged adults. Our study design of 6 months of intervention (1 g AKG vs placebo) will allow us to understand the effect of AKG treatment on DNA methylation, and another 3 months of post-intervention follow-up will help us understand if there is any long-term effect of AKG. In order to minimize recruitment bias, our study design is double-blinded.

Inclusion criteria

• participants whose biological age (as measured by blood DNA methylation) is greater than their chronological age

Exclusion criteria

• pregnant women
• more than ONE of the following chronic medical conditions (based on the medical history and during screening), they are NOT eligible to participate in the study:

• Waist circumference more than or equal to 90 cm for males or more than or equal to 80 cm for females
• Fasting triglycerides more than or equal to 1.7 mmol/l
• High-density lipoprotein less than 1.0 mmol/l in men or less than 1.3 mmol/l in women
• Blood pressure more than or equal to 130/85 mmHg or use of antihypertensive medication
• Fasting glucose more than or equal to 6.0 mmol/l
• Osteopenia
• Mild Osteoarthritis not interfering in daily activities
• Fatty liver
• Participants will NOT be recruited if they fall in the following categories:

• Pre-existing, or history of major CVD (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (under 3 or more than 3 prescribed medications), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism
• Type 1 diabetes and Type 2 diabetes under oral metformin or insulin therapy and with diabetic complications such as diabetic retinopathy, diabetic nephropathy
• Active cancer or treatment of cancer in the last 3 years
• Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications)
• Pregnant women will not be recruited into this study because of the safety issues associated with X-ray irradiation during DXA scan
• Potential female participants who plan on pregnancy within the next 9 months of study period
• Multiple sclerosis and autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease
• Recent history of sepsis or infection (within 3 months of in-patient hospitalization)
• Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders
• Any metal implants in the body
• Hepatitis and Liver cirrhosis (independent of severity)
• Severe kidney disease (GFR less than 30 ml/min/1.73 m2)
• Skin disease (on oral or systemic medication for immune system)
• Subjects receiving any other similar investigational product within 60 days or 5 halflives before the screening, whichever that is longer
• Any serious medical illness which in the PI's judgment may jeopardize the subject by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study